• licensing agreement

GenKOre Announces Collaboration with a US-based Company on In vivo Gene-editing Therapy

PRNewswire January 26, 2023

SEOUL, South Korea, Jan. 26, 2023 /PRNewswire/ — GenKOre, Inc., a Korea-based biotech company with hypercompact┬áCRISPR-Cas tools,┬áannounced that it has┬áentered into┬áa┬ástrategic research collaboration with a US-based┬ábiopharma┬ácompany for the development of┬áin vivo┬ágene┬áediting┬átherapies. This┬ácollaboration will utilize┬áGenKOre’s┬áproprietary┬áCRISPR-Cas┬áplatform,┬áTaRGET┬á(Tiny nuclease,┬áaugment┬áRNA-based┬áGenome┬áEditing┬áTechnology). The┬áTaRGET┬áplatform is distinct from the most popular┬ágenome editing technology,┬áCRISPR-Cas9,┬áin that the whole editing module can be delivered with a single AAV vector. Based on┬átheir┬áTaRGET platform,┬áGenKOre┬áhas developed different┬ámodalities┬áof editing tools including┬áTaRGET-CUT,┬áTaRGET-Adenine Base Editing (ABE),┬áTaRGET-AI (Gene Activation and Inhibition system).┬áand┬áTaRGET-FREE┬á(Gene knock-in)┬á.┬á

“This collaboration reflects the strength and┬ápotential┬áutility of┬áTaRGET┬áplatform in the application of┬áin vivo┬ágene-editing therapy”, said Yong-Sam Kim, CEO┬áof┬áGenKOre. “Not only will this collaboration provide an opportunity to validate the applicability of┬áTaRGET┬áplatform to┬áin vivo┬átherapy, but we will also expand the utility of our technologies to a wider spectrum of rare diseases.” The collaboration┬áwas┬ábuilt on the mutual┬áinterest┬áin┬áforging transformative therapeutics for patients with rare diseases.┬á

Under the terms of the agreement, GenKOre will receive up to 300 million USD including an upfront, option exercise fees and milestone payments upon successful achievement of R&D and commercial milestones across two in vivo disease targets. In addition, GenKOre will receive research funding and tiered royalties up to a double-digit percentage of net sales. 


AAPR aggregates press releases and media statements from around the world to assist our news partners with identifying and creating timely and relevant news.

All of the press releases published on this website are third-party content and AAP was not involved in the creation of it. Read the full terms.